An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations

INTRODUCTION: Frontotemporal lobar degeneration–causing mutations in the progranulin (GRN) gene reduce progranulin protein (PGRN) levels, suggesting that restoring PGRN in mutation carriers may be therapeutic. Nimodipine, a Food and Drug Administration–approved blood-brain barrier-penetrant calcium...

Descripción completa

Detalles Bibliográficos
Autores principales: Sha, Sharon J., Miller, Zachary A., Min, Sang-won, Zhou, Yungui, Brown, Jesse, Mitic, Laura L., Karydas, Anna, Koestler, Mary, Tsai, Richard, Corbetta-Rastelli, Chiara, Lin, Sophie, Hare, Emma, Fields, Scott, Fleischmann, Kirsten E., Powers, Ryan, Fitch, Ryan, Martens, Lauren Herl, Shamloo, Mehrdad, Fagan, Anne M., Farese, Robert V., Pearlman, Rodney, Seeley, William, Miller, Bruce L., Gan, Li, Boxer, Adam L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671622/
https://www.ncbi.nlm.nih.gov/pubmed/29124108
http://dx.doi.org/10.1016/j.trci.2017.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671622/
https://www.ncbi.nlm.nih.gov/pubmed/29124108
http://dx.doi.org/10.1016/j.trci.2017.08.002

Ejemplares similares